AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2702922 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed comparison group (excluding subjects with remitted disorder)
Number of subjects: 0
Study 781795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate mouthrinse
Number of subjects: 28
Study 781795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31610437 — intervention group
Group type: EXPERIMENTAL
Intervention: Short film featuring a young individual with personal experience of depression and suicidality (n=81)
Number of subjects: 158
Study 31610437 — intervention group
Group type: COMPARATOR
Intervention: Thematically unrelated control film (n=77)
Number of subjects: 158
Study 30475165 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (given for four days)
Number of subjects: 1149
Study 30475165 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1149
Study 28586856 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced primary care
Number of subjects: 721
Study 28586856 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced primary care plus coaching
Number of subjects: 721
Study 28586856 — intervention group
Group type: COMPARATOR
Intervention: Control (Enhanced primary care)
Number of subjects: 721
Study 26590240 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies‐To‐Enhance‐Practice (STEPs) intervention
Number of subjects: 20
Study 26590240 — intervention group
Group type: COMPARATOR
Intervention: Control ASPs
Number of subjects: 20
Study 23237154 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based recall (Pop-recall)
Number of subjects: 195
Study 23237154 — intervention group
Group type: COMPARATOR
Intervention: Practice-based recall (PCP-recall)
Number of subjects: 195
Study 21767688 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing from self-reported healers (healing condition)
Number of subjects: 60
Study 21767688 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control condition)
Number of subjects: 60
Study 19095873 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intertendinous approach
Number of subjects: 109
Study 19095873 — intervention group
Group type: COMPARATOR
Intervention: Classic posterior approach
Number of subjects: 109
Study 17066108 — intervention group
Group type: EXPERIMENTAL
Intervention: Less stigmatising attitude towards people with psychiatric illness
Number of subjects: 84
Study 17066108 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, levels of education, and belief in causation of mental illness
Number of subjects: 84
Study 15503070 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-fracture care needs assessment
Number of subjects: 332
Study 15503070 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in ability to walk, form of housing, mortality, and level of care and help
Number of subjects: 332
Study 15503070 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal and informal support
Number of subjects: 332
Study 15503070 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial support and institutional care
Number of subjects: 332
Study 10983860 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 225
Study 10983860 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin 700 mg twice daily for 10 days
Number of subjects: 225
Study 8814030 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled continuous orthodontic force of 50 cN applied to the maxillary right premolar
Number of subjects: 56
Study 8814030 — intervention group
Group type: COMPARATOR
Intervention: Contralateral premolar (control)
Number of subjects: 56
Study 1593357 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (hypocaloric enteral nutrition on postnatal days 3 to 5)
Number of subjects: 27
Study 1593357 — intervention group
Group type: COMPARATOR
Intervention: Late feeding (enteral nutrition on postnatal days 10 to 14)
Number of subjects: 27
Study 3882106 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (fifth day)
Number of subjects: 742
Study 3882106 — intervention group
Group type: COMPARATOR
Intervention: Late mobilisation (tenth day)
Number of subjects: 742
Study 30481229 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with 4 children
Number of subjects: 1135
Study 30481229 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with ≥5 children
Number of subjects: 1135
Study 30481229 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment of one birth in women
Number of subjects: 1135
Study 30481229 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 1135
Study 27162127 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training programme
Number of subjects: 86
Study 27162127 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 86
Study 26187490 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 4656
Study 26187490 — intervention group
Group type: COMPARATOR
Intervention: Sputum microscopy
Number of subjects: 4656
Study 24101769 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hair cortisol during the second and third trimester
Number of subjects: 100
Study 24101769 — intervention group
Group type: EXPERIMENTAL
Intervention: Child hair cortisol levels at year 1 and 3
Number of subjects: 100
Study 24101769 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of child hair cortisol
Number of subjects: 100
Study 24101769 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of hair cortisol
Number of subjects: 100
Study 20498136 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of lorazepam
Number of subjects: 21
Study 20498136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19112786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of pre-oxygenated HBOC-201
Number of subjects: 0
Study 19112786 — intervention group
Group type: COMPARATOR
Intervention: Dry occlusion (without HBOC-201 infusion)
Number of subjects: 0
Study 16404407 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine 10 mg once daily plus behavioral therapy
Number of subjects: 46
Study 16404407 — intervention group
Group type: COMPARATOR
Intervention: behavioral therapy alone (control)
Number of subjects: 46
Study 12699797 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen section of the endocervical margin of the cone specimen
Number of subjects: 203
Study 12699797 — intervention group
Group type: COMPARATOR
Intervention: No frozen section of the endocervical margin of the cone specimen
Number of subjects: 203
Study 10805062 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine (4 mg q.d.)
Number of subjects: 0
Study 10805062 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine (2 mg b.i.d.)
Number of subjects: 0
Study 10805062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg q.d.)
Number of subjects: 0
Study 10805062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8916563 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0
Study 8916563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1497864 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 8
Study 1497864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6507132 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 60
Study 6507132 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 60
Study 4028596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m pyrophosphate (PYP) with 3.4 mg of stannous chloride
Number of subjects: 34
Study 4028596 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m methylene diphosphonate (MDP) with 3.4 mg of stannous chloride
Number of subjects: 34
Study 4028596 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m methylene diphosphonate (MDP) with 1.0 mg of stannous chloride
Number of subjects: 34
Study 29741196 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-hour physical activity module including a one-hour exercise tutorial combined with a 30-minute practical counselling session
Number of subjects: 161
Study 29741196 — intervention group
Group type: COMPARATOR
Intervention: Control group (2015)
Number of subjects: 161
Study 26619359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 0
Study 26619359 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 0
Study 24611852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Smokers (MTS)
Number of subjects: 196
Study 24611852 — intervention group
Group type: COMPARATOR
Intervention: Usual care therapy (Controls)
Number of subjects: 196
Study 23772084 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 120
Study 23772084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20533631 — intervention group
Group type: EXPERIMENTAL
Intervention: Centripetal open‐sandwich technique
Number of subjects: 30
Study 20533631 — intervention group
Group type: COMPARATOR
Intervention: Centripetal closed‐sandwich technique
Number of subjects: 30
Study 25160920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated with alcohol
Number of subjects: 417
Study 25160920 — intervention group
Group type: COMPARATOR
Intervention: Not intoxicated with alcohol
Number of subjects: 417
Study 16888045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient cooling protocol
Number of subjects: 88
Study 14639675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (1.5 mg t.i.d.)
Number of subjects: 30
Study 14639675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (1.5 mg t.i.d.)
Number of subjects: 30
Study 14639675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11049977 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpanded CD34-selected PBPCs
Number of subjects: 121
Study 11049977 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded PBPCs
Number of subjects: 121
Study 11049977 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 121
Study 8676625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m2 per day on days 1-5 for six courses)
Number of subjects: 196
Study 8676625 — intervention group
Group type: COMPARATOR
Intervention: CAP (cyclophosphamide 750 mg/m2 per day and doxorubicin 50 mg/m2 per day on day 1, and prednisone 40 mg/m2 per day on days 1-5 for six courses)
Number of subjects: 196
Study 8676625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine in pretreated cases
Number of subjects: 196
Study 8676625 — intervention group
Group type: COMPARATOR
Intervention: CAP in pretreated cases
Number of subjects: 196
Study 8676625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine in untreated cases
Number of subjects: 196
Study 8676625 — intervention group
Group type: COMPARATOR
Intervention: CAP in untreated cases
Number of subjects: 196
Study 8676625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and CAP (side effects)
Number of subjects: 196
Study 1736033 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (50% carbohydrate calories, 30% fat calories, 20% protein calories)
Number of subjects: 12
Study 1736033 — intervention group
Group type: COMPARATOR
Intervention: Fat-based diet (28% carbohydrate calories, 55% fat calories, 17% protein calories)
Number of subjects: 12
Study 6093845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily
Number of subjects: 19
Study 6093845 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of ketoconazole
Number of subjects: 19
Study 6093845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30449625 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab
Number of subjects: 987
Study 30449625 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy plus cisplatin
Number of subjects: 987
Study 28265973 — intervention group
Group type: COMPARATOR
Intervention: Weight gain in overweight and obese women
Number of subjects: 1173
Study 28265973 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in overweight and obese women
Number of subjects: 1173
Study 28265973 — intervention group
Group type: COMPARATOR
Intervention: Stable weight in overweight and obese women
Number of subjects: 1173
Study 25289840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training with concurrent blood flow restriction (BFR)
Number of subjects: 40
Study 25289840 — intervention group
Group type: COMPARATOR
Intervention: Low-load resistance training alone (control)
Number of subjects: 40
Study 23945213 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI-168
Number of subjects: 0
Study 23945213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22016276 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 1 mg/kg/day (Group A)
Number of subjects: 120
Study 22016276 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 1 mg/kg alternate day (Group B)
Number of subjects: 120
Study 22016276 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 1 mg/kg/day for one week/four weeks (Group C)
Number of subjects: 120
Study 22016276 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 20 mg every alternate day for 16 weeks (Group D)
Number of subjects: 120
Study 22016276 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 19076262 — intervention group
Group type: EXPERIMENTAL
Intervention: COPEing with Toddler Behaviour parent training program
Number of subjects: 79
Study 19076262 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 79
Study 16883263 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, followed by 75 mg/day after Day 2) in addition to conventional therapy (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Number of subjects: 107
Study 16883263 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Number of subjects: 107
Study 15151582 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized course of dexamethasone
Number of subjects: 33
Study 15151582 — intervention group
Group type: COMPARATOR
Intervention: Standard 42-day course of dexamethasone
Number of subjects: 33
Study 11216738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 0.5 million KIU before incision and 0.5 million KIU during initiation of cardiopulmonary bypass
Number of subjects: 202
Study 11216738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 9928580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 662
Study 9928580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years) plus Goserelin (2 years)
Number of subjects: 662
Study 9928580 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (3 years)
Number of subjects: 662
Study 9928580 — intervention group
Group type: COMPARATOR
Intervention: Alternating adjuvant chemotherapy
Number of subjects: 662
Study 9928580 — intervention group
Group type: COMPARATOR
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 662
Study 8035946 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/d) for 1 week
Number of subjects: 75
Study 8035946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3270665 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-01 (controlled release strips containing ofloxacin) applied site (T)
Number of subjects: 27
Study 3270665 — intervention group
Group type: COMPARATOR
Intervention: Placebo-applied site (P)
Number of subjects: 27
Study 3270665 — intervention group
Group type: COMPARATOR
Intervention: Control site (C)
Number of subjects: 27
Study 1232533 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 50
Study 1232533 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) plus a 4‐week course of cyclophosphamide (DES + CTX)
Number of subjects: 50
Study 30488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprox 500® (2 tablets/day for 6 weeks)
Number of subjects: 63
Study 30488800 — intervention group
Group type: COMPARATOR
Intervention: Serenoa repens (320 mg, 1 tablet/day for 6 weeks)
Number of subjects: 63
Study 28723906 — intervention group
Group type: EXPERIMENTAL
Intervention: GBLUP
Number of subjects: 0
Study 28723906 — intervention group
Group type: EXPERIMENTAL
Intervention: PBayesB
Number of subjects: 0
Study 28723906 — intervention group
Group type: EXPERIMENTAL
Intervention: PBayesA
Number of subjects: 0
Study 28723906 — intervention group
Group type: EXPERIMENTAL
Intervention: PBayesCπ
Number of subjects: 0
Study 25434394 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation
Number of subjects: 0
Study 25434394 — intervention group
Group type: COMPARATOR
Intervention: In vitro bioassay using sera from matched patients
Number of subjects: 0
Study 23531379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus fluid resuscitation
Number of subjects: 3600
Study 23531379 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard of care without bolus fluid)
Number of subjects: 3600
Study 21921100 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 1 (referral if at least 1 of the following criteria is present: inflammatory back pain, HLA‐B27, or sacroiliitis detected by imaging)
Number of subjects: 560
Study 21921100 — intervention group
Group type: COMPARATOR
Intervention: Strategy 2 (referral if 2 out of 5 criteria are positive: inflammatory back pain, HLA‐B27, sacroiliitis detected by imaging, positive family history of ankylosing spondylitis, or good treatment response to NSAIDs)
Number of subjects: 560
Study 19734968 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (preferred treatment)
Number of subjects: 0
Study 19734968 — intervention group
Group type: COMPARATOR
Intervention: Various treatment modalities (not specified)
Number of subjects: 0
Study 16846517 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Manual intervention
Number of subjects: 250
Study 16846517 — intervention group
Group type: COMPARATOR
Intervention: Deferred intervention (control)
Number of subjects: 250
Study 15315512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 1052
Study 15315512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 1052
Study 15315512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 1052
Study 15315512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 15315512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (effective dose range 150-600 mg/day)
Number of subjects: 1052
Study 15315512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (two times daily vs three times daily)
Number of subjects: 1052
Study 11143188 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day intravenous eflornithine (100 mg/kg every 6 h)
Number of subjects: 321
Study 11143188 — intervention group
Group type: COMPARATOR
Intervention: 14-day regimen of eflornithine
Number of subjects: 321
Study 9269608 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 66
Study 9269608 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine and bacterial immunostimulant
Number of subjects: 66
Study 8371842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (I test)
Number of subjects: 0
Study 8371842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test with contralateral non-noxious stimulus (II test)
Number of subjects: 0
Study 8371842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test with contralateral noxious stimulus (III test)
Number of subjects: 0
Study 3690187 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG Glaxo (Evans Medical Ltd, Dunstable, UK)
Number of subjects: 21
Study 3690187 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG Pasteur (L'Institut Pasteur, France)
Number of subjects: 21
Study 31997715 — intervention group
Group type: EXPERIMENTAL
Intervention: ZILVER PTX stent
Number of subjects: 220
Study 31997715 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 220
Study 29695250 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls Active programme
Number of subjects: 1752
Study 29695250 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 1752
Study 26879049 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (n = 34)
Number of subjects: 69
Study 24096751 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist during simulated trauma resuscitation
Number of subjects: 0
Study 24096751 — intervention group
Group type: COMPARATOR
Intervention: No checklist during simulated trauma resuscitation
Number of subjects: 0
Study 22094636 — intervention group
Group type: EXPERIMENTAL
Intervention: TetraMen-T (alternative formulations)
Number of subjects: 378
Study 22094636 — intervention group
Group type: COMPARATOR
Intervention: Neisvac-C (licensed adjuvanted serogroup C conjugate vaccine)
Number of subjects: 378
Study 20797475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan (SDG) 100 mg/d
Number of subjects: 30
Study 20797475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan (SDG) 20 mg/d
Number of subjects: 30
Study 20797475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18996857 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet (35-45% of energy, >20% as monounsaturated fatty acids; n = 54)
Number of subjects: 131
Study 18996857 — intervention group
Group type: EXPERIMENTAL
Intervention: LF diet (20-30% of energy; n = 51)
Number of subjects: 131
Study 18996857 — intervention group
Group type: COMPARATOR
Intervention: Control diet (35% of energy as fat; n = 26)
Number of subjects: 131
Study 16640064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 118
Study 16640064 — intervention group
Group type: COMPARATOR
Intervention: Tinnitus Masking (TM)
Number of subjects: 118